Alyeska Investment Group L.P. Buys Shares of 125,000 CeriBell (NASDAQ:CBLL)

Alyeska Investment Group L.P. purchased a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 125,000 shares of the company's stock, valued at approximately $3,235,000. Alyeska Investment Group L.P. owned about 0.35% of CeriBell as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in CBLL. FMR LLC acquired a new stake in CeriBell in the 4th quarter valued at about $128,120,000. ABG WTT Global Life Science Capital Partners GP Ltd acquired a new stake in CeriBell during the fourth quarter worth approximately $28,160,000. RA Capital Management L.P. bought a new position in shares of CeriBell in the fourth quarter worth about $21,340,000. Vanguard Group Inc. acquired a new position in shares of CeriBell during the fourth quarter worth $18,015,000. Finally, Board of Trustees of The Leland Stanford Junior University acquired a new position in CeriBell during the 4th quarter worth about $16,143,000.

Insider Buying and Selling at CeriBell

In other news, CEO Xingjuan Chao sold 15,628 shares of CeriBell stock in a transaction dated Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total value of $236,139.08. Following the completion of the transaction, the chief executive officer now owns 727,151 shares in the company, valued at $10,987,251.61. This trade represents a 2.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 24,700 shares of company stock worth $372,434 over the last three months.

CeriBell Trading Up 1.8%

CBLL stock traded up $0.29 during midday trading on Monday, hitting $16.26. The company's stock had a trading volume of 86,850 shares, compared to its average volume of 271,740. The company's 50-day moving average is $18.06. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. As a group, analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CBLL shares. LADENBURG THALM/SH SH started coverage on CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 price target for the company. Canaccord Genuity Group restated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.